Companies / ImmunityBio

ImmunityBio

Company

Related drugs: 8
Related conditions: 4

Recent developments

31 Jul 26	ImmunityBio Q1 Revenue Beats Estimates, But Loss Widens and Pipeline Advances	biospace.com ↗
23 Jun 26	FDA Approvals and Pipeline Expansion Drive Bladder Cancer Therapeutics Market Growth	urotoday.com ↗
21 Jun 26	New Research Advances Cancer Immunotherapy Through Clinical Data, Resistance Mechanisms, and Microbiome Insights	nature.com ↗
20 May 26	FDA accepts ImmunityBio sBLA for ANKTIVA plus BCG in papillary bladder cancer	theglobeandmail.com ↗
17 May 26	ImmunityBio Says Saudi FDA Encouraged rBCG Filing and ANKTIVA Expansion Talks	firstwordpharma.com ↗
25 Apr 26	ImmunityBio launches ANKTIVA in Saudi Arabia after accelerated lung cancer approval	biospace.com ↗
02 Apr 26	Clinical Trial Advances in Cancer Immunotherapy and Targeted Therapies	targetedonc.com ↗
30 Mar 26	ImmunityBio's Anktiva Gains NCCN Guideline Inclusion for Bladder Cancer	cancernetwork.com ↗
04 Mar 26	ImmunityBio Expands Cancer Immunotherapy Access in Saudi Arabia and MENA Region	oncodaily.com ↗
27 Feb 26	ImmunityBio Completes Enrollment in ANKTIVA Plus BCG Trial for Bladder Cancer	biospace.com ↗

Headlines link to the original publisher. Sources limited to a reviewed list of journals, regulators, and medical press.